The Week in Review: OriGene Technologies Acquires Zhongshan Biotech
Published: Mar 19, 2012
March 17, 2012 -- OriGene Technologies, a US research tool maker, acquired Beijing Zhongshan Golden Bridge Biotech, which makes oncology pathology products; Zhejiang Hisun Pharma and Piedmont Pharma of the US will jointly develop products for the pet segment of the animal health market; China has allocated $8 million to set up a Global Clinical Trial and Research Center in Tianjin Biotechnology Research Park; China’s aggressive cost-cutting of drug prices, especially generics, has put a cloud over the country’s drug makers; Beijing has closed the pharmacies in two of its 22 public hospitals on a trial basis to implement a healthcare reform goal; Boehringer Ingelheim will invest $15.7 million to build an R&D center in Shanghai’s Zhangjiang HiTech Park; Bayer Healthcare plans to increase its China revenues up to $3.3 billion by 2015; InflammaGen™ Therapeutics is planning a China strategy with help from ChinaBio®; and Sihuan Pharma’s application to begin clinical trials of a new treatment for hypertension was accepted by the SFDA. More details….
Stock Symbols: (SHE: 600267) (HK: 0460)